


TCPOBOP

Cat. No.:	HY-103243	
CAS No.:	76150-91-9	
Molecular Formula:	C ₁₆ H ₈ Cl ₄ N ₂ O ₂	
Molecular Weight:	402.06	
Target:	Bcl-2 Family	
Pathway:	Apoptosis	
Storage:	Powder	-20°C 3 years
	In solvent	-80°C 6 months
		-20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (62.18 mM); ultrasonic and warming and heat to 50°C)				
	Preparing Stock Solutions	Solvent \ Mass \ Concentration	1 mg	5 mg	10 mg
		1 mM	2.4872 mL	12.4360 mL	24.8719 mL
		5 mM	0.4974 mL	2.4872 mL	4.9744 mL
		10 mM	0.2487 mL	1.2436 mL	2.4872 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (6.22 mM); Suspended solution; Need ultrasonic				
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.22 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	TCPOBOP is a constitutive androstane receptor (CAR) agonist that induces robust hepatocyte proliferation and hepatomegaly without any liver injury or tissue loss ^[1] . TCPOBOP attenuates Fas-induced murine liver injury by altering Bcl-2 proteins ^[2] .
IC ₅₀ & Target	Bcl-2
In Vivo	TCPOBOP (oral; 3 mg/kg; 1-5 days) remarkable increases Liver weight to body weight in LW/BW ratio at 48 hours ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MET ^{fl/fl} ; Tam-Cre ^{+/+} mice with a targeted deletion for exon 16 with MET KO ^[1]
Dosage:	3 mg/kg
Administration:	Oral; 1, 2, 5 days
Result:	Increased Liver weight to body weight.

CUSTOMER VALIDATION

- Pharmacol Res. 2020 Nov;161:105110.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Bhushan B, et al. TCPOBOP-Induced Hepatomegaly and Hepatocyte Proliferation are Attenuated by Combined Disruption of MET and EGFR Signaling. *Hepatology*. 2019 Apr;69(4):1702-1718.
- [2]. Baskin-Bey ES, et al. Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins. *Hepatology*. 2006 Jul;44(1):252-62.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA